Curcumin, a p300 HAT inhibitor, prevents the development of hypertension-induced left ventricular hypertrophy in rats
Hidetoshi Suzuki1, Tatsuya Morimoto1, Yoichi Sunagawa1,2,5, Teruhisa Kawamura2, Tomohide Takaya2,4, Hiromichi Wada2, Kazuhide Uemura1, Akira Shimatsu3, Takeshi Kimura4, Masatoshi Fujita5, Koji Hasegawa2.
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
- Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan.
- Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan.
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
World Congress of the International Society for Heart Research 2010 (Kyoto, Japan), 2010/05/13 (Poster).
Abstract
Background and Objective: Recently, we found that curcumin inhibits p300 histone acetyltransferase activity and prevents deterioration of systolic function at the late stage of salt-sensitive Dahl rats (DS). However, whether curcumin prevents the development of left ventricular hypertrophy (LHV) at the early stage of hypertensive heart disease is unclear.
Methods: Six-week-old DS (n = 19) and control salt-resistant Dahl rats (DR, n = 10) were given a high-salt diet and randomly assigned to daily oral treatment with 50 mg/kg/day of curcumin or its vehicle for 6 weeks.
Results: There were no differences in any data examined before treatment between the curcumin and vehicle groups. After treatment (at 12 weeks of age), the LV wall thickness, LV mass and LV fractional shortening were significantly higher in DS compared with DR, and the LV end-systolic and end-diastolic dimensions were significantly smaller in DS than in DR. LV fractional shortening in DS was similar between the curcumin and vehicle groups. However, curcumin treatment significantly (p < 0.0001) decreased the LV wall thickness in DS, but not in DR. Curcumin also significantly (p < 0.001) decreased the LV mass in DS, but not in DR.
Conclusions: Curcumin inhibits the development of hypertensioninduced concentric LVH without affecting the systolic function. Thus, this compound might be applicable to patients with early stage of hypertensive heart disease as well as advanced stage of this disease.